Explorna Therapeutics sp. z o.o.
Research and experimental development on biotechnology
Overview
Explorna Therapeutics is a company that develops mRNA as a therapeutic platform and offers novel cap analogs for mRNA vaccines and therapeutics. They provide technology and therapeutic programs to pharmaceutical partners, aiming to advance disease treatment and prevention.
Financials
Revenue history (in k)
Filing timeliness
No financial statement for 2025 – the filing deadline has passed.
- 2025not filed
- 202427/06/2025
- 202315/05/2024
- 202223/06/2023
- 202127/06/2022
- 202001/09/2021
Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.
Statistics
How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2024.
Results vs industry
Industry
Offer
- mRNA cap analogs
- mRNA nucleotides
- Synthetic mRNA
- Biotechnology testing
Websites
- explorna.comHomepage - ExploRNAWooCommerce 11.2WordPress 7.1Google Tag ManagerYoast SEOWWPMLLLiteSpeed
Trademarks
The company holds 1 active trademark registered with the Polish Patent Office. The first mark was filed in 2021.
| Mark | Protected until | |
|---|---|---|
| EXPLORNA (word) | Jan 20, 2031 |
Authorized Representatives
Manner of representation
The right to represent the company is vested in two members of the management board acting jointly, or in a member of the management board acting jointly with a commercial proxy.
Ownership
| Owner | Shares | Share value | Stake |
|---|---|---|---|
Jacek Jemielity age 53 | 42 | $567.26 | 23.0769% |
Ms Galleon Gmbh | 87 | $1,175.04 | 47.8022% |
Joanna Kowalska | 18 | $243.11 | 9.8901% |
Marek Rafał Baranowski | 9 | $121.56 | 4.9451% |
| 9 | $121.56 | 4.9451% | |
Jakub Adam Gołąb age 54 | 8 | $108.05 | 4.3956% |
Dominika Anna Nowis | 5 | $67.53 | 2.7473% |
Mateusz Gołąb age 53 | 4 | $54.02 | 2.1978% |
Beneficial owners
| Person | Rights |
|---|---|
Capital group
The company belongs to the MS Galleon GmbH (Austria) group, which is its direct owner. The group has 15 companies, 5 of them abroad.
| Name | Country |
|---|---|
| Barlinek | |
| Barlinek Inwestycje | |
| Cersanit | |
| Ekovoltis | |
| FTF Columbus |
Bank accounts
Registered as a VAT taxpayer on 2020-04-22.
06 1090 2590 0000 0001 5196 1835
28 1090 2590 0000 0001 5153 7743
92 1090 2590 0000 0001 5153 7852
Debt
No entries in the National Debtors Register (KRZ).
Public aid
4 public aid cases recorded, with a total value of $5,784,945.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Apr 25, 2025 | Aid for research and development projects: industrial research | $804.2K$804,226 | Prezes Agencji Badań Medycznych | |
| Apr 21, 2020 | De minimis aid (in accordance with Commission Regulation No 1407/2013 or earlier) | $3,846$3,846 | Uniwersytet Warszawski | |
| Apr 16, 2020 | Aid for research and development projects: industrial research | $3.9M$3,909,336 | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2020-01-01 | Development of experimental anticancer immunotherapy based on therapeutic mRNAs modified with innovative next-generation cap analogues | $5M$4,976,873 | Operational Programme Smart Growth |
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
| BDO register entry | Active |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| Biotechna S.A. | $2,472,888.07 | bsbiotechna.com | ||
| Captor Therapeutics S.A. | $2,286,539.43 | captortherapeutics.pl | ||
| Precisionlife Poland sp. z o.o. | $617,020.34 | precisionlife.com | ||
| Famicordtx S.A. | $589,673.84 | famicordtx.com | ||
| Camino Science sp. z o.o. | $557,065.18 | camino.science | ||
| Pharmena S.A. | $541,436.46 | pharmena.eu | ||
| Vaxican sp. z o.o. | $390,933.79 | vaxican.com | ||
| Medicofarma Biotech S.A. | $314,882.33 | medicofarmabiotech.pl | ||
| Multiqure S.A. | $284,781.52 | purebiologics.com | ||
| WPD Pharmaceuticals S.A. | $87,561.70 | wpdpharmaceuticals.pl |
Change history
| Date | Event | |
|---|---|---|
| 2023-11-28 | Share capital increase (8,350.00 PLN → 9,100.00 PLN) | |
| 2023-03-01 | Address change (Ul. Żwirki I Wigury 101/0.30, 02-089, Warszawa → Ul. Żwirki I Wigury 93/2157, 02-089, Warszawa) | |
| 2022-07-20 | Share capital increase (7,600.00 PLN → 8,350.00 PLN) | |
| 2022-02-07 | Share capital increase (6,850.00 PLN → 7,600.00 PLN) | |
| 2021-06-10 | Share capital increase (6,250.00 PLN → 6,850.00 PLN) |
FAQ
Last updated: 2026-04-13